How does Canada compare to international markets in terms of time to launch, proportion of launches and sequence in launch for new medicines?
A new report shows a sharp decline in the number of new drug launches in Canada in 2019.
Up until 2018, Canada was increasingly getting faster and more extensive market-access to therapies relative to other countries. The research shows a sharp decline in the number of new drug launches in Canada in 2019, from 22 in 2018 to just 13 in 2019.
In the last quarter of 2019, there was only one new drug launch in Canada.
Among 37 new therapies launched globally in 2018, over half of them (21) were not launched in Canada. The majority of the medicines not commercialized in Canada were for rare diseases and cancer.
This drop in market-access also coincides with Canada's new federal price controls for patented medicines